Human Platelets Take up Anti-VEGF Agents

被引:3
作者
Sobolewska, B. [1 ]
Fehrenbacher, B. [2 ]
Muenzer, P. [3 ]
Kalbacher, H. [4 ]
Geue, S. [3 ]
Stellos, Konstantinos [5 ,6 ]
Schaller, M. [2 ]
Ziemssen, F. [1 ]
机构
[1] Eberhard Karls Univ Tuebingen, Ctr Ophthalmol, Tubingen, Germany
[2] Eberhard Karls Univ Tuebingen, Dept Dermatol, Tubingen, Germany
[3] Univ Tubingen, Dept Cardiol & Cardiovasc Med, Tubingen, Germany
[4] Eberhard Karls Univ Tuebingen, Interfac Inst Biochem, Tubingen, Germany
[5] Newcastle Univ, Biosci Inst, Vasc Biol & Med Theme, Newcastle Upon Tyne, Tyne & Wear, England
[6] Newcastle Hosp NHS Fdn Trust, Dept Cardiol, Newcastle Upon Tyne, Tyne & Wear, England
关键词
ARTERIAL THROMBOEMBOLIC EVENTS; RECEPTOR-MEDIATED ENDOCYTOSIS; ACUTE CORONARY SYNDROMES; NEONATAL FC-RECEPTOR; CIRCULATING PLATELETS; ACTIVATE PLATELETS; SYSTEMIC SAFETY; CD34(+) CELLS; RICH PLASMA; FACTOR-I;
D O I
10.1155/2021/8811672
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. Growing evidence suggests different systemic exposure of anti-vascular endothelial growth factor (anti-VEGF) agents with repeated intravitreal application. Since the penetration of anti-VEGF agents through vascular barrier was reported, the interaction of anti-VEGF with nonresident platelets has become a topic of interest. The purpose of this study was to evaluate, with the help of visualization techniques, whether platelets take up the anti-VEGF agents ranibizumab, aflibercept, and bevacizumab. Methods. The uptake of anti-VEGF agents with or without VEGF treatment was investigated using immunofluorescence and immunogold staining in human platelets. The role of actin filaments and clathrin-coated vesicles in the transport of ranibizumab, aflibercept, and bevacizumab was evaluated by two pharmacologic inhibitors: staurosporine (protein kinase C inhibitor) and cytochalasin D. Results. All three anti-VEGF agents were taken up by platelets and colocalized with VEGF. Ranibizumab and aflibercept were mainly detected in alpha-granules; however, bevacizumab was equally localized in alpha-granules and in platelet vesicles. Both staurosporine and cytochalasin D completely inhibited the uptake of aflibercept into platelets. Both pharmacological inhibitors also decreased the transport of ranibizumab and bevacizumab into platelets. Bevacizumab was significantly more frequently colocalized within clathrin-coated vesicles than ranibizumab and aflibercept. Conclusion. All three anti-VEGF agents are taken up by platelets and internalized in alpha-granules, which may result in a higher local exposure of anti-VEGF after the activation of platelets, potentially contributing to arterial thromboembolic events. Clathrin-coated vesicles seem to be more prominent in the transport of bevacizumab than ranibizumab and aflibercept. Nevertheless, whether the different localization and transport of bevacizumab are truly related to specific differences of receptor-mediated endocytosis has to be revealed by further research.
引用
收藏
页数:12
相关论文
共 82 条
[1]   Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers [J].
Alio, Jorge L. ;
Abad, Marta ;
Artola, Alberto ;
Rodriguez-Prats, Jose L. ;
Pastor, Silvia ;
Ruiz-Colecha, Jose .
OPHTHALMOLOGY, 2007, 114 (07) :1286-1293
[2]   Basic Principles of Platelet Biology and Clinical Implications [J].
Angiolillo, Dominick J. ;
Ueno, Masafumi ;
Goto, Shinya .
CIRCULATION JOURNAL, 2010, 74 (04) :597-607
[3]   SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB [J].
Avery, Robert L. ;
Castellarin, Alessandro A. ;
Steinle, Nathan C. ;
Dhoot, Dilsher S. ;
Pieramici, Dante J. ;
See, Robert ;
Couvillion, Stephen ;
Nasir, Ma'an A. ;
Rabena, Melvin D. ;
Maia, Mauricio ;
Van Everen, Sherri ;
Le, Kha ;
Hanley, William D. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (10) :1847-1858
[4]   Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema A Systematic Review and Meta-analysis [J].
Avery, Robert L. ;
Gordon, Gabriel M. .
JAMA OPHTHALMOLOGY, 2016, 134 (01) :21-29
[5]   Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD [J].
Avery, Robert L. ;
Castellarin, Alessandro A. ;
Steinle, Nathan C. ;
Dhoot, Dilsher S. ;
Pieramici, Dante Joseph ;
See, Robert ;
Couvillion, Stephen ;
Nasir, Ma'an A. ;
Rabena, Melvin D. ;
Le, Kha ;
Maia, Mauricio ;
Visich, Jennifer E. .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2014, 98 (12) :1636-1641
[6]   Role of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and Thrombosis [J].
Badimon, Lina ;
Suades, Rosa ;
Fuentes, Eduardo ;
Palomo, Ivan ;
Padro, Teresa .
FRONTIERS IN PHARMACOLOGY, 2016, 7
[7]   Dynasore impairs VEGFR2 signalling in an endocytosis-independent manner [J].
Basagiannis, Dimitris ;
Zografou, Sofia ;
Galanopoulou, Katerina ;
Christoforidis, Savvas .
SCIENTIFIC REPORTS, 2017, 7
[8]   Constitutive Endocytosis of VEGFR2 Protects the Receptor against Shedding [J].
Basagiannis, Dimitris ;
Christoforidis, Savvas .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (32) :16892-16903
[9]   Hypertension and Ischemic Stroke After Aflibercept for Retinopathy of Prematurity [J].
Bazvand, Fatemeh ;
Pour, Elias Khalili ;
Gharehbaghi, Golnaz ;
Faghihi, Hooshang ;
Khodabande, Alireza ;
Bahar, Mohammadreza Mehrabi ;
Riazi-Esfahani, Hamid .
INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2020, 13 :243-247
[10]  
Berezin AE, 2019, J Unexplored Med Data, V4, P4, DOI DOI 10.20517/2572-8180.2019.05